Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.35 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28928093 | 0.82 | FPR2 (0.39) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL21233125 | 0.81 | CA12 (0.42) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL1126836 | 0.81 | PLA2G10 (0.39) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL20383847 | 0.81 | AKR1B1 (0.41) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL22572118 | 0.78 | AKR1B1 (0.39) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL9371797 | 0.78 | KDM4E (0.40) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL28928213 | 0.74 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2AHDAC6PLA2G10 | |
| SCHEMBL14865350 | 0.74 | AKR1B1 (0.55) | KDM4EALDH1A1L3MBTL1POLBMAPT | |
| SCHEMBL26757682 | 0.73 | CA12 (0.41) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL3586455 | 0.72 | ALPL (0.47) | KDM4EALDH1A1KMT2AHDAC6PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CA12 4642/4885CA1 4407/4885CA2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.